Amid accusations of inflating sales figures, New Horizon Health (HKG:6606) saw the resignation of Chairman and CEO Zhu Yeqing on Dec. 30, 2024, South China Morning Post reported.
The board also removed him as an executive director. Yao Naxin, a non-executive director, will now serve as board chairman, according to the report.
Earlier in 2024, the early cancer screening company's CFO and auditor also resigned following accusations from a short seller that New Horizon Health had inflated its 2022 sales figures.
Trading in the company's shares has been suspended since March 27, 2024, and will remain so until it meets resumption requirements, the publication said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。